Recursion, a drug discovery firm, releases Q3 results Nov 6, skips earnings call, updates on merger Nov 20.
Recursion, a clinical-stage techbio firm focused on drug discovery, will release its Q3 2024 results on November 6, 2024, but will not hold a traditional earnings call. Instead, an update will follow its proposed merger with Exscientia on November 20, 2024. The call will be streamed on social media platforms, allowing for viewer questions. Headquartered in Salt Lake City, Recursion employs advanced machine learning to enhance drug discovery.
October 30, 2024
3 Articles